AVINZA™ Will ContributeSignificant Value to our LSPP Portfolio
New sales force in place to target general
pain centers; launched in 2Q with ~80 reps total
True once-daily dosing, unique dual-release formulation, comparatively smooth PK profile
U.S. sustained-release opioid market is $2.3 billion, largest initial market we’ve entered
Negotiating with Elan to co-promote in U.S.